Stay updated on SHR6390 & Pyrotinib in HER2+ Breast Cancer Clinical Trial

Sign up to get notified when there's something new on the SHR6390 & Pyrotinib in HER2+ Breast Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the SHR6390 & Pyrotinib in HER2+ Breast Cancer Clinical Trial page

  1. Check
    4 days ago
    No Change Detected
  2. Check
    11 days ago
    Change Detected
    Summary
    Major change: page now carries a government-operating-status notice and a new version tag (v3.2.0) replacing the old one (v3.1.0).
    Difference
    13%
    Check dated 2025-10-06T05:32:53.000Z thumbnail image
  3. Check
    18 days ago
    Change Detected
    Summary
    Version updated from v3.0.2 to v3.1.0; no other content changes detected.
    Difference
    0.3%
    Check dated 2025-09-29T03:04:53.000Z thumbnail image
  4. Check
    25 days ago
    No Change Detected
  5. Check
    33 days ago
    Change Detected
    Summary
    Revision updated from v3.0.1 to v3.0.2; the 'Back to Top' element was removed.
    Difference
    0.8%
    Check dated 2025-09-14T19:15:43.000Z thumbnail image
  6. Check
    40 days ago
    Change Detected
    Summary
    The web page has been updated from version 3.0.0 to version 3.0.1.
    Difference
    0.8%
    Check dated 2025-09-07T15:31:07.000Z thumbnail image
  7. Check
    47 days ago
    Change Detected
    Summary
    The web page has undergone significant changes with the addition of a facility name and location details, while several location-related terms have been removed.
    Difference
    7%
    Check dated 2025-08-31T11:57:45.000Z thumbnail image
  8. Check
    61 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.11 to version 2.16.12.
    Difference
    0.3%
    Check dated 2025-08-17T04:18:50.000Z thumbnail image

Stay in the know with updates to SHR6390 & Pyrotinib in HER2+ Breast Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the SHR6390 & Pyrotinib in HER2+ Breast Cancer Clinical Trial page.